2011
Best Doctors
New York Magazine

1985
Fellow
American Academy of Neurology

1979
Teacher-Investigator Award
NINCDS

1968
Alpha omega alpha
New York University School of Medicine

1964
Phi beta kappa
Mu chapter of Massachusetts, Brandeis University

Database and Registry

New York State Consortium of Multiple Sclerosis Centers (establishing MS registry and database to be used for multiple collaborative projects)

Clinical Trials

A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis
Researchers want to find out if an investigational drug called BAF312 (Siponimod) is safe and can help people with SPMS. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

Open-label proof-of-concept trial to evaluate the response to Acthar Gel therapy in patients with MS relapses who have failed to make adequate recovery after treatment with IV methylprednisolone
Although ACTHAR gel is approved for the treatment of acute relapses it is currently not widely used. Thus we are conducting a small open-label proof-of-concept trial to evaluate the response to ACTHAR gel therapy in patients who have failed to make a satisfactory recovery after t...

Miller A, Bourdette D, Cohen JA, Coyle PK, Lublin F, Paty DW, Rice GP, Weinstock-Guttman B, editors. Multiple Sclerosis. New York, Continuum; 1999. pp1-196.

Miller A. Paroxysmal Disorders. In: Burks JS, Johnson KP, editors. Multiple Sclerosis. Diagnosis, Medical Management and Rehabilitation. New York, Demos Medical Publishing, Inc.; 2000.

Miller A, Herndon RM. Treatment Issues. In: Kalb RC, editor. Multiple Sclerosis. The questions you have-the answers you need. Second New York, Demos Medical Publishing, Inc.; 2000.

Miller A. Clinical Features. In: Cook SD, editor. Handbook of Multiple Sclerosis. Third New York, Marcel Dekker, Inc.; 2001.

Sand IK, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 Feb;.

Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Neurology 2014 Oct; 13(10).

Miller AE, Macdonell R, Comi G, Freedman MS, Kappos L, Mäurer M, Olsson TP, Wolinsky JS, Bozzi S, Dive-Pouletty C, O'Connor PW. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. Journal of neurology 2014 Sep; 261(9).

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014 Jul; 83(3).

Sand IK, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 Feb;.

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 May; 20(6).

Miller AE, Cohen BA, Krieger SC, Markowitz CE, Mattson DH, Tselentis HN. Constructing an adaptive care model for the management of disease-related symptoms throughout the course of multiple sclerosis--performance improvement CME. Multiple sclerosis (Houndmills, Basingstoke, England) 2014 Jan; 20(1).

.;.

O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of neurology 2013 Oct; 260(10).

Rudick RA, Miller AE. Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis. Neurology 2012 Jun; 78(24).

Miller AE, Rhoades RW. Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. Current opinion in neurology 2012 Feb; 25 Suppl.